Find a story

Search Spins

Search titles, summaries, and missing voices across published articles — press releases, announcements, and media coverage.

6 results for “drug development”

SPIN Processed News Frame: The Halo

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Kalshi and Polymarket launched prediction markets tied to clinical trial outcomes, drawing criticism from researchers who argue such markets risk enabling insider trading and distorting drug development incentives, while the platforms counter that they improve patient access to trial information.

Spin 72% Claim Present in Source AI Risk Moderate
NPR Technology

Aug 8, 2026

SPIN Processed News Frame: The Shield

Doctors and researchers worry that FDA-related wagers on Kalshi and Polymarket could compromise drug development tests and erode public trust in the process (Rebecca Robbins/New York Times)

Medical professionals and researchers express concern that prediction markets like Kalshi and Polymarket—where users bet on FDA regulatory decisions—are creating perverse incentives that could distort clinical trial design, influence drug development priorities, and undermine public confidence in the FDA approval process.

Spin 35% Claim Present in Source AI Risk Moderate
Techmeme

Jul 29, 2026

SPIN Processed News Frame: The Hype

How AI is supercharging drug development - Axios

The article reports on AI's accelerating role in drug discovery and development, highlighting speed, cost reduction, and novel target identification — but provides no specific case studies, timelines, or validation metrics.

Spin 78% Needs Evidence AI Risk High
Axios AI via Google News

Published Jul 20, 2026 · Analyzed Aug 3, 2026

SPIN Processed News Frame: The Halo

Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable

Anthropic has announced it is initiating internal drug discovery programs targeting diseases deemed unprofitable by major pharmaceutical companies, positioning itself as a non-commercial actor in biomedical R&D.

Spin 82% Claim Present in Source AI Risk High
The Decoder

Published Jul 4, 2026 · Analyzed Jul 6, 2026

SPIN Processed News Frame: The Hype

How a Google DeepMind Spin-off Hunts Hidden Drug Targets

Isomorphic Labs, a Google DeepMind spin-off, launched its Isomorphic Drug Design Engine (IsoDDE) to improve AI-driven drug discovery by predicting protein-ligand interactions, pocket identification, and binding affinity—addressing limitations of AlphaFold3 in novel target spaces.

Spin 78% Source-Supported AI Risk High Needs Evidence
IEEE Spectrum AI

Published Jun 11, 2026 · Analyzed Jul 4, 2026

SPIN Processed News Frame: The Hype

How AI may speed up drug development - Axios

The article reports on speculative potential for AI to accelerate drug development timelines and reduce costs, without citing specific trials, validated models, or regulatory approvals.

Spin 75% Needs Evidence AI Risk High
Axios AI via Google News

Published Jul 16, 2019 · Analyzed Jul 6, 2026